The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntercede Regulatory News (IGP)

Share Price Information for Intercede (IGP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 109.50
Bid: 107.00
Ask: 112.00
Change: 4.50 (4.29%)
Spread: 5.00 (4.673%)
Open: 105.00
High: 109.50
Low: 109.00
Prev. Close: 105.00
IGP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Director

20 Oct 2023 07:03

RNS Number : 7955Q
Intercede Group PLC
20 October 2023
 

20 October 2023

 

INTERCEDE GROUP plc

('Intercede', the 'Company' or the 'Group')

Appointment of Non-Executive Director

Intercede, the leading specialist in digital identity, credential management and secure mobility, is pleased to announce the appointment of Daniel O'Brien to the Board of Intercede as a Non-Executive Director with immediate effect.

 

Mr. O'Brien ('Dan') brings over 30 years' experience in financial roles across successful listed, PE backed and privately owned international organisations. Dan studied at the University of Cambridge prior to qualifying as a chartered accountant at Deloitte in 1991 where he spent 8 years working in Audit Assurance. He has held senior finance roles in a range of multinational companies including COLT Telecoms, Eidos Plc, Huveaux Plc as Group Finance Director, Shine Group as Chief Financial Officer and Tarsus Group as both Chief Financial Officer and Chief Operating Officer. At Tarsus, Dan was a lead executive overseeing the take private acquisition by Charterhouse and the subsequent sale of the business to Informa plc for approximately $1bn. Dan currently sits on the advisory board of several organisations including Cuil Bay Capital.

 

Royston Hoggarth, Chair of Intercede, commented:

 

"We are delighted to announce Dan's appointment as a Non-Executive Director. He brings a wealth of public and private company experience, and his strong technical, financial and commercial acumen will be of great value as we continue to execute our growth plans. Additionally, he will be appointed as Audit Chair with immediate effect, with Tina Whitley moving to Remuneration Chair and John Linwood as Nominations Chair."

 

ENQUIRIES

Intercede Group plc

Tel. + 44 (0)1455 558111

Klaas van der Leest

CEO

Nitil Patel

CFO

 

 

Cavendish Capital Markets Limited

Tel. + 44 (0)20 7220 0500

Simon Hicks/Fergus Sullivan

Corporate Finance

Tim Redfern/Charlotte Sutcliffe

ECM

 

About Intercede

Intercede is a cybersecurity software company specialising in digital identities, and its innovative solutions enable organisations to protect themselves against the number one cause of data breach: compromised user credentials.

 

The Intercede suite of products allows customers to choose the level of security that best fits their needs, from Secure Registration and ID Verification to Password Security Management, One-Time Passwords, FIDO and PKI. Uniquely, Intercede provides the entire set of authentication options from Passwords to PKI, supporting customers on their journey to passwordless and stronger authentication environments. In addition to developing and supporting Intercede software, the Group offers professional services and custom development capabilities as well as managing the world's largest password breach database.

 

For over 20 years, global customers in government, aerospace and defence, financial services, healthcare, telecommunications, cloud services and information technology have trusted Intercede solutions and expertise in protecting their mission critical data and systems at the highest level of assurance.

For more information visit: www.intercede.com

 

INFORMATION REQUIRED UNDER RULE 17 AND SCHEDULE 2, PARAGRAPH (G) OF THE AIM RULES FOR COMPANIES ("AIM RULES")

Full name:

Daniel Philip O'Brien

Age:

56

Shareholding in the Company:

53,644

Current directorships and/or partnerships:

Historic directorships and/or partnerships (within the last five years):

 

 Cuil Bay Capital Ltd

Raccoon Media Group Limited

School-Home Support Service (UK)

AMB Tarsus Exhibitions SDN BHD

CapRegen BioSciences Limited

CapRegen Limited

CapRegen Magnum Limited

CapRegen Natural BioSciences Limited

CapRegen Nutraceuticals Limited

Fairs & Exhibitions (1992) Limited

Fairs And Exhibitions Limited

Metabolic Medical Institute, Inc.

PNO Exhibition Investment (Dubai) Limited

PT. Tarsus Indonesia SEA

Shenzhen Bo Ao Exhibition Co., Ltd

Smarter Shows (Tarsus) Limited

Tarsus America Limited

Tarsus Atlantic Limited

Tarsus Cardio, Inc.

Tarsus Cedar Limited

Tarsus China Limited

Tarsus Exhibition (Shanghai) Co., Ltd

Tarsus Exhibition (Shenzhen) Co., Ltd

Tarsus Exhibitions & Publishing Limited

Tarsus Exhibitions India Private Limited

Tarsus Group Limited

Tarsus Group Limited (Jersey Entity)

Tarsus Holdings Limited

Tarsus Investments Limited

Tarsus Leeward Limited

Tarsus Luzhniki Limited

Tarsus Martex

Tarsus Medical Limited

Tarsus New Media Limited

Tarsus Organex Limited

Tarsus Overseas Limited

Tarsus Publishing Limited

Tarsus Touchstone Limited

Tarsus UK Holdings Limited

Tarsus US Limited

Tarsus Windward Limited

Tiger Acquisitions (Jersey) Limited

Tiger Acquisitions Holding Limited

Tiger Acquisitions Intermediate Holding Limited

Tiger Acquisitions UK Limited

W.R.Kern Organisation Limited(The)

F&E (2008) Limited

Connect Biz, LLC

Tak Mexico Holdings, LLC

Tarsus Connect, LLC

Tarsus Map LLC

 

 

There is no further information to be disclosed in relation to the appointment pursuant to Rule 17 and Schedule 2, paragraph (g) of the AIM Rules.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGLBDGGGDDGXG
Date   Source Headline
14th Apr 20207:00 amRNSDirector/PDMR Shareholding
7th Apr 20207:00 amRNSTrading Update
3rd Apr 20205:07 pmRNSShare Incentive Plan
31st Mar 20207:00 amRNSReceipt of $4.6m Order
28th Feb 20207:00 amRNSShare Incentive Plan
26th Feb 20209:50 amRNSShare Incentive Plan
25th Feb 20207:00 amRNSShare Incentive Plan
12th Feb 202011:22 amRNSShare Award
25th Nov 20197:00 amRNSHalf-year Report
7th Oct 20197:00 amRNSTrading Update
30th Sep 20197:00 amRNSDirector/PDMR Shareholding
18th Sep 20196:30 pmRNSResult of AGM
16th Sep 20193:56 pmRNSPosting of Annual Report & Notice of AGM
17th Jun 20197:00 amRNSAppointment of Non-Executive Director
5th Jun 20197:00 amRNSFinal Results
8th Apr 20197:00 amRNSSale of Property
2nd Apr 20197:00 amRNSTrading Update
28th Feb 20197:00 amRNSNew Contract Win
4th Feb 20193:19 pmRNSHolding(s) in Company
17th Dec 201810:19 amRNSBoard Change
26th Nov 20187:00 amRNSHalf-year Report
22nd Oct 20187:00 amRNSGrant of Options
4th Oct 20187:00 amRNSTrading Statement
20th Sep 20187:00 amRNSResult of AGM
4th Sep 20187:00 amRNSDirector/PDMR Shareholding
10th Aug 20187:00 amRNSDirector/PDMR Shareholding
31st Jul 20187:00 amRNSDirector/PDMR Shareholding
10th Jul 20188:00 amRNSDirector/PDMR Shareholding
29th Jun 20184:59 pmRNSPDMR Shareholding
7th Jun 20187:00 amRNSFinal Results
26th Apr 20182:10 pmRNSPDMR Change
25th Apr 20187:00 amRNSDirector/PDMR Shareholding
20th Apr 201812:15 pmRNSPDMR Change
11th Apr 201811:36 amRNSHolding(s) in Company
11th Apr 20187:00 amRNSAppointment of Chief Executive
4th Apr 20187:00 amRNSReceipt of $4.0m Order/Trading Update
29th Mar 20187:00 amRNSDirectorate Change
9th Mar 20187:00 amRNSNew Contract Award
13th Feb 20187:00 amRNSNew Contract Award
4th Dec 20177:00 amRNSContract
30th Nov 20177:00 amRNSNew Contract Award
27th Nov 20177:00 amRNSHalf-year Report
6th Nov 20171:58 pmRNSTrading Update
26th Oct 20177:00 amRNSShare Award
5th Oct 20177:00 amRNSTrading Statement
13th Sep 20173:30 pmRNSResult of AGM
13th Sep 20177:00 amRNSDirectorate Change
25th Aug 20177:00 amRNSIssue of Convertible Loan Notes
1st Aug 20179:07 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSShare Incentive Plan & Issue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.